Therefore, the ratio of stem cell-like CD8+ T cells increased by about 2.28-fold in the PαCD3&LIGHT group compared to the Blank group (Figure 3S), and thus Ki67-positive self-renewing T cells augmented by about 3.45-fold (Figure 3T), driving long-term tumor-specific immune response by maintaining a pool of effector T cells. The gene discussed is CD8A; the disease is neoplasm.